4 results about "Quinine" patented technology

This invention discloses a rapid mass spectrometry method and kit for the simultaneous detection of multiple components in body fluids, belonging to the field of biological detection and identification technology. It can rapidly detect trace compounds such as drugs and biomarkers in complex biological samples. This kit mainly utilizes loaded functional materials to achieve extraction and enrichment of target analytes and is equipped with a quick connector for coupling with a detector to achieve rapid detection. Compared with traditional methods, the significant advantages of the method established by this kit are that it does not require complex sample pretreatment, allows for micro-quantitative sampling, requires small sample volumes, facilitates convenient storage of biological samples, is easy to operate, does not require specialized technical personnel, and enables rapid on-site detection when coupled with portable mass spectrometry. This kit has been successfully used for the detection of quinine, procainamide hydrochloride, atenolol, and nortriptyline in complex samples such as blood and serum, and has significant clinical and economic value.

The application provides application of a TAS2R4 agonist in preparation of a drug for treating and preventing diabetic nephropathy, and comprises that a bitter taste receptor 4 subtype (TAS2R4) can be used as a drug target point for treating and preventing diabetic nephropathy, and quinine is used as a TAS2R4 agonist. Specifically, mouse diabetic nephropathy induced by a chemical reagent and mouse podocyte cell line MPC cell damage caused by chronic high glucose are taken as research objects, it is found that mouse TAS2R4 agonist quinine has a prevention and treatment effect on diabetic nephropathy, has a protection effect on podocyte loss caused by high glucose, and has an activation effect on mouse kidney TAS2R4 molecular signal, and a possible molecular mechanism is discussed from the aspects of inhibiting NLRP3 inflammasome activation and NF-kappa B signal activation path, and theoretical basis and technical support are provided for prevention and treatment of diabetic nephropathy, other kidney diseases with inactivation of TAS2R4 molecular signal and other diseases by using TAS2R4 agonists including quinine.

This invention discloses a method for determining the bitterness of hydrolyzed milk protein and its application. The method includes: (1) enzymatically hydrolyzing casein samples using a neutral protease suitable for reaction at 40-55℃. (2) after enzymatic hydrolysis, inactivating the enzyme, centrifuging the hydrolyzed sample, and taking the supernatant for descriptive sensory evaluation; simultaneously, sensory evaluation of a series of quinine solutions with different concentration gradients is performed to obtain their bitterness values. (3) by correlating samples with different degrees of hydrolysis and different concentrations of quinine through sensory scoring, a functional relationship curve is constructed, and the corresponding mathematical model is obtained. (4) by comparing samples with different degrees of hydrolysis and quinine solutions with different concentration ranges, the quinine concentration corresponding to a quinine selectivity of 50% is obtained, and the quinine concentration-intensity curve of the enzymatically hydrolyzed samples under different degrees of hydrolysis is obtained, so that the quinine equivalent value of samples with different degrees of hydrolysis can be calculated. Therefore, this invention provides ideas and methods for solving the problem that bitterness in dairy products is difficult to quantitatively describe and predict.

The application provides application of quinofine or a synthetic bacterium thereof in treatment of diseases related to mutation of tyrosyl-tRNA synthetase. The quinofine or the synthetic bacterium thereof can restore defects caused by mutation of tyrosyl-tRNA synthetase, and thus can be used for treatment of diseases related to mutation of human tyrosyl-tRNA synthetase, such as Charcot-Marie-Tooth disease type C and infantile onset multi-system neurologic, endocrine and pancreatic disease type 2, or reproduction defects of Caenorhabditis elegans.